疫苗前血浆可溶性炎症指标水平负向预测HCV与HIV感染者的HAV、HBV及破伤风疫苗应答
在ACTG 5232与CFAR0910临床试验中,检测HCV现症感染(n=15)、HIV感染(n=24)及未感染对照(n=10)接种前血浆IP10、IL-6、sCD163和sCD14水平,并给予加速程序HAV/HBV疫苗与破伤风加强针,于0、1、3、8、24周测抗体应答。HCV与HIV感染者接种前IP10、IL-6、sCD14升高,HCV感染者sCD163亦升高;接种后HCV与HIV感染者的HAV和HBV抗体应答低于且不如未感染对照持久;在HCV感染者中,接种前IP10、IL-6、sCD14和sCD163水平与疫苗后HAV、HBV和破伤风抗体应答呈负相关。
要点
- HCV与HIV感染者接种前血浆IP10、IL-6、sCD14升高,HCV感染者sCD163亦升高。
- HCV与HIV感染者接种HAV/HBV疫苗后抗体应答低于且不如未感染对照持久。
- HCV感染者接种前IP10、IL-6、sCD14、sCD163与HAV、HBV和破伤风抗体应答呈负相关。
核心结论
- 在HCV与HIV感染期间,全身炎症标志物反映免疫功能障碍,表现为对HAV/HBV新抗原疫苗应答不良。
研究设计与样本
- ACTG 5232与CFAR0910临床试验,检测HCV现症感染(n=15)、HIV感染(n=24)及未感染对照(n=10)接种前血浆IP10、IL-6、sCD163和sCD14水平,给予加速程序HAV/HBV疫苗与破伤风加强针,于0、1、3、8、24周测抗体应答。
主要发现
- HCV与HIV感染者接种前血浆IP10、IL-6、sCD14水平升高,HCV感染者sCD163亦升高。
- HIV感染者接种前破伤风抗体水平低于未感染对照,而HCV与HIV感染者疫苗诱导的抗体应答完整。
- 接种HAV/HBV疫苗后,HCV与HIV感染者的HAV和HBV抗体应答低于且不如未感染对照持久。
- 在HCV感染者中,接种前血浆IP10、IL-6、sCD14和sCD163水平与疫苗后HAV、HBV和破伤风抗体应答呈负相关。
- HIV感染者HAV/HBV疫苗应答低,无法评估免疫相关因素。
局限性
- HIV感染者HAV/HBV疫苗应答低,无法评估免疫相关因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear. METHODS: ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10, IL-6, sCD163 and sCD14 were measured in viremic HCV- (n = 15) or HIV-infected participants (n = 24) and uninfected controls (n = 10). Accelerated dosing HAV/HBV vaccine and tetanus booster were administered and antibody response was measured at 0, 1, 3, 8, and 24 weeks. RESULTS: Pre-vaccine plasma IP10, IL-6, and sCD14 levels were elevated in both HCV and HIV-infected participants, while sCD163 was also elevated in HCV-infected participants. Pre-immunization tetanus antibody levels were lower in HIV-infected than in uninfected participants, while vaccine induced antibody responses were intact in HCV and HIV-infected participants. After HAV/HBV vaccination, HCV and HIV-infected participants had lower and less durable HAV and HBV antibody responses than uninfected controls. Among HCV-infected participants, pre-vaccine plasma IP10, IL-6, sCD14, and sCD163 levels inversely correlated with HAV, HBV and tetanus antibody responses after vaccine. Low HAV/HBV vaccine responses in HIV-infected participants prohibited assessment of immune correlates. CONCLUSIONS: During HCV and HIV infection markers of systemic inflammation reflect immune dysfunction as demonstrated by poor response to HAV/HBV neo-antigen vaccine.
引用
- Shive CL, Judge CJ, Clagett B, et al. Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. Vaccine. 2017. PMID: 29254840. doi:10.1016/j.vaccine.2017.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。